EverSource Wealth Advisors LLC Sells 426 Shares of Exelixis, Inc. (NASDAQ:EXEL)

EverSource Wealth Advisors LLC decreased its holdings in shares of Exelixis, Inc. (NASDAQ:EXEL) by 16.1% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 2,227 shares of the biotechnology company’s stock after selling 426 shares during the quarter. EverSource Wealth Advisors LLC’s holdings in Exelixis were worth $52,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the business. LSV Asset Management boosted its position in shares of Exelixis by 1,651.4% in the first quarter. LSV Asset Management now owns 2,774,707 shares of the biotechnology company’s stock valued at $65,844,000 after acquiring an additional 2,616,278 shares during the period. Los Angeles Capital Management LLC lifted its stake in shares of Exelixis by 948.3% in the first quarter. Los Angeles Capital Management LLC now owns 2,454,277 shares of the biotechnology company’s stock valued at $58,240,000 after buying an additional 2,220,150 shares during the period. True Wealth Design LLC acquired a new stake in Exelixis during the fourth quarter worth about $828,000. Intech Investment Management LLC increased its stake in Exelixis by 155.8% during the first quarter. Intech Investment Management LLC now owns 100,039 shares of the biotechnology company’s stock valued at $2,374,000 after acquiring an additional 60,925 shares during the period. Finally, GSA Capital Partners LLP acquired a new position in Exelixis in the 1st quarter valued at approximately $1,281,000. Institutional investors and hedge funds own 85.27% of the company’s stock.

Exelixis Stock Down 1.1 %

Shares of EXEL opened at $25.96 on Friday. Exelixis, Inc. has a 12-month low of $18.64 and a 12-month high of $27.83. The firm has a market capitalization of $7.87 billion, a PE ratio of 40.56, a price-to-earnings-growth ratio of 0.56 and a beta of 0.54. The stock’s fifty day simple moving average is $25.56 and its 200-day simple moving average is $23.48.

Exelixis (NASDAQ:EXEL) last announced its quarterly earnings data on Tuesday, August 6th. The biotechnology company reported $0.75 earnings per share for the quarter, beating the consensus estimate of $0.31 by $0.44. Exelixis had a net margin of 17.38% and a return on equity of 15.54%. The business had revenue of $637.18 million for the quarter, compared to analyst estimates of $468.21 million. Analysts anticipate that Exelixis, Inc. will post 1.59 EPS for the current year.

Insider Transactions at Exelixis

In related news, EVP Jeffrey Hessekiel sold 25,000 shares of the company’s stock in a transaction dated Monday, September 23rd. The stock was sold at an average price of $26.38, for a total value of $659,500.00. Following the completion of the sale, the executive vice president now owns 605,325 shares in the company, valued at $15,968,473.50. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. In other news, EVP Jeffrey Hessekiel sold 25,000 shares of the business’s stock in a transaction dated Monday, September 23rd. The stock was sold at an average price of $26.38, for a total transaction of $659,500.00. Following the completion of the transaction, the executive vice president now directly owns 605,325 shares in the company, valued at approximately $15,968,473.50. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, CFO Christopher J. Senner sold 125,000 shares of the stock in a transaction that occurred on Friday, August 9th. The shares were sold at an average price of $27.19, for a total transaction of $3,398,750.00. Following the completion of the sale, the chief financial officer now owns 721,680 shares in the company, valued at $19,622,479.20. The disclosure for this sale can be found here. Insiders have sold 327,858 shares of company stock worth $8,640,129 in the last three months. Insiders own 2.85% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research firms have recently issued reports on EXEL. Oppenheimer restated an “outperform” rating and set a $29.00 price objective on shares of Exelixis in a research report on Tuesday, July 30th. HC Wainwright restated a “buy” rating and issued a $29.00 price objective on shares of Exelixis in a research note on Wednesday, September 18th. JMP Securities reaffirmed a “market outperform” rating and set a $29.00 price objective on shares of Exelixis in a report on Friday, September 20th. UBS Group initiated coverage on Exelixis in a research report on Thursday, September 19th. They set a “neutral” rating and a $30.00 target price for the company. Finally, StockNews.com raised Exelixis from a “buy” rating to a “strong-buy” rating in a report on Saturday, July 13th. Five research analysts have rated the stock with a hold rating, ten have given a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $27.67.

Exelixis Company Profile

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.